Fresenius Medical Care, the world’s leading provider of dialysis products and services, announced today the appointment of Dr. Frank Maddux, 61, the company’s Global Chief Medical Officer, to the Management Board. He will start in his new position on January 1, 2020. 

Dr. Maddux was appointed Global Chief Medical Officer in March of this year with the goal of enhancing cooperation and the exchange of medical knowledge across the Fresenius Medical Care network, in order to ensure high-quality outcomes for patients worldwide. Now, by adding this position to the Management Board, Fresenius Medical Care is further underlining its commitment to applying clinical science at an ever-higher level. 

Dr. Maddux is a physician, IT entrepreneur and healthcare executive with more than 30 years of experience in healthcare. He has been with Fresenius Medical Care since 2009. Before his appointment as Global Chief Medical Officer, he served as Executive Vice President for Clinical & Scientific Affairs and Chief Medical Officer for Fresenius Medical Care North America, where he was responsible for the delivery of high-quality, value-based care for the largest integrated renal care network in the United States. His great expertise and research interests have focused on the quality of care for chronic kidney disease patients.

Stephan Sturm, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said: “As Global Chief Medical Officer, Dr. Frank Maddux enjoys an outstanding reputation both inside and outside of Fresenius Medical Care. With his proven medical competence and experience, which he can contribute, he will be a great addition to the company’s Management Board.” 

Rice Powell, Chief Executive Officer of Fresenius Medical Care and Chairman of the Management Board, said: “Dr. Frank Maddux will be key to our ability to drive value for our patients by pursuing new and evolving medical opportunities, such as a more-focused home therapies offering, regenerative medicine, and enhancing our Care Coordination business model throughout the world. We are fortunate to have a Global Chief Medical Officer as qualified and experienced as Dr. Maddux joining our Management Board.” 

Dr. Maddux said: “The well-being of our patients is our priority, and key to our company’s success. To continuously deliver on this global commitment, I am moved by the power of ideas, conceived by individuals, molded by collective intelligence and brought to life by investment in a higher purpose that is dedicated to improving the lives of people. I am proud of the importance that medical science has for Fresenius Medical Care.”

A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist^® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

The healthcare group Fresenius has nearly completed the work begun two years ago to expand company headquarters in Bad Homburg. Two new office buildings; “EK3” at Else-Kröner Street and “D15A” located at Daimler Street have been in operation since April. Now the redesigned exterior grounds fronting Else-Kröner Street are completed. These grounds link the additions with existing buildings to create the new “Fresenius Campus.”

To mark the occasion, the company leadership yesterday invited employees who work on the premise to a “Campus Fest.” Together with Bad Homburg Lord Mayor Alexander Hetjes and Fresenius Chief Executive Officer Stephan Sturm, they celebrated this new milestone in Fresenius company history.

In opening remarks, Stephan Sturm emphasized the ongoing growth at Fresenius, both worldwide and in the spa city. “Only 10 years ago we had about 2,000 employees in Bad Homburg. Now we have twice as many. All the signs point to continued growth in the future – because demand for our products and services is growing worldwide, and because our employees are doing everything they can to meet this demand.”

“The company’s headquarters also symbolizes the impressive growth of Fresenius, which continues to make its mark on Bad Homburg as a business location,” said Hetjes. “The energy efficiency is exemplary, and thanks to the headquarters’ campus character and modern design the company can offer employees a very attractive working environment in our city.”

Construction on EK3 began in September, 2017. The five-story building accommodates 600 modern office workspaces, conference rooms, an additional employee cafeteria and an underground parking garage. Work on D15A began in May, 2018. This building expands on the existing Research & Development Center of Fresenius Medical Care, to which it is connected by a footbridge. It offers 150 office workspaces spread over six floors.

Altogether Fresenius invested 70 million euros in the headquarters expansion. The company currently employs about 4,000 people in Bad Homburg and another 300 in neighboring Oberursel.

Construction on another office building to be rented by Fresenius, Uniqus 2 at Horex Street, is expected to be finished by the end of this year. The building will accommodate 250 workspaces.